Oncology Medical News about Cetuximab, rash, colon cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group Study N0147
Oncology (Karger), 07/23/09

Jatoi A et al. - In a study to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials, it was concluded that men and younger pts are at greater risk for severe cetuximab-induced rash although overall the risk is low. These observations are particularly important in designing future rash prevention and palliation trials.

Methods

933 cetuximab-treated pts enrolled on N0147, an adjuvant chemotherapy trial for colon cancer, were evaluated for clinical risk factors of severe rash.

Results

50 pts (5%) developed a severe rash (grade 3).
More men vs women developed such a rash: 34 (7%) vs 16 (3%).
A greater number of younger pts (<70 yrs of age) also developed a rash: 48 (6%) vs 2 (1%).
Race and performance score were not predictive.

<< Previous
Generation of a concise gene panel for outcome prediction in...

Next >>
Age-specific prevalence of HPV genotypes in cervical cytology...